NCT02429791 - Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1) | Biotech Hunter

Enrollment

510

Participants

Timeline

Start Date

April 14, 2015

Primary Completion Date

September 16, 2016

Study Completion Date

May 30, 2023

Conditions

HIV Infections

Interventions

DRUG

DTG 50 mg

Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.

DRUG

RPV 25 mg

Participants received one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.

DRUG

CAR

CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI

Trial Locations (65)

100

GSK Investigational Site, Taipei

813

GSK Investigational Site, Kaohsiung City

1000

GSK Investigational Site, Brussels

2000

GSK Investigational Site, Antwerp

2010

GSK Investigational Site, Darlinghurst

3181

GSK Investigational Site, Prahran

4000

GSK Investigational Site, Liège

9000

GSK Investigational Site, Ghent

11217

GSK Investigational Site, Taipei

18016

GSK Investigational Site, Granada

20009

GSK Investigational Site, Washington D.C.

20099

GSK Investigational Site, Hamburg

20127

GSK Investigational Site, Milan

20142

GSK Investigational Site, Milan

20146

GSK Investigational Site, Hamburg

21080

GSK Investigational Site, Huelva

24501

GSK Investigational Site, Lynchburg

25123

GSK Investigational Site, Brescia

28034

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

28805

GSK Investigational Site, Alcalá de Henares

29020

GSK Investigational Site, Málaga

29600

GSK Investigational Site, Marbella

31401

GSK Investigational Site, Savannah

32803

GSK Investigational Site, Orlando

34982

GSK Investigational Site, Ft. Pierce

41013

GSK Investigational Site, Seville

41041

GSK Investigational Site, Seville

46015

GSK Investigational Site, Valencia

60590

GSK Investigational Site, Frankfurt

60596

GSK Investigational Site, Frankfurt

63108

GSK Investigational Site, St Louis

69437

GSK Investigational Site, Lyon

75018

GSK Investigational Site, Paris

75246

GSK Investigational Site, Dallas

75571

GSK Investigational Site, Paris

75651

GSK Investigational Site, Paris

77098

GSK Investigational Site, Houston

80336

GSK Investigational Site, München

90019

GSK Investigational Site, Los Angeles

90069

GSK Investigational Site, Los Angeles

90813

GSK Investigational Site, Long Beach

92380

GSK Investigational Site, Garches

94115

GSK Investigational Site, San Francisco

105275

GSK Investigational Site, Moscow

196645

GSK Investigational Site, Saint Petersburg

214006

GSK Investigational Site, Smolensk

302040

GSK Investigational Site, Oryol

420061

GSK Investigational Site, Kazan'

08103

GSK Investigational Site, Camden

C1425AWK

GSK Investigational Site, Ciudad Autonoma de Buenos Aire

K1H 8L6

GSK Investigational Site, Ottawa

G1V 4G2

GSK Investigational Site, Québec

M5B 1W8

GSK Investigational Site, Toronto

M5G 2N2

GSK Investigational Site, Toronto

V6Z 2C7

GSK Investigational Site, Vancouver

V8W 1M8

GSK Investigational Site, Victoria

3015 CE

GSK Investigational Site, Rotterdam

3079 DZ

GSK Investigational Site, Rotterdam

08003

GSK Investigational Site, Barcelona

03203

GSK Investigational Site, Elche

07010

GSK Investigational Site, Palma de Mallorca

07198

GSK Investigational Site, Palma de Mallorca

E1 1BB

GSK Investigational Site, London

M8 5RB

GSK Investigational Site, Manchester